|
|
|
Overview |
|
|
Definition |
|
Myocardial infarction (MI) is the result of continuous and/or complete
reduction in blood flow to a portion of the myocardium, thus producing some
degree of myocardial death and necrosis. Oxygen deprivation results from
blockage of coronary arteries supplying blood to the myocardium typically
brought on by atherosclerotic plaque. Total coronary artery occlusion results in
acute MI with Q-wave formation (non–Q wave infarctions
have greatly narrowed infarct-related artery without total obstruction).
Introduction of coronary care units in the 1960s and recent practices of urgent
reperfusion and advances in pharmacologic interventions have decreased mortality
rates from 30% to 40%, to 15% to 20% of admissions. |

|
|
Etiology |
|
- Atherosclerosis, resulting in narrowed or occluded
arteries
- Thrombosis, the immediate cause, caught within atherosclerotic
plaque
- Coronary vasomotor spasm
- Coronary artery embolism
- Congenital anomalies
- Arteritis
- Trauma
|

|
|
Risk Factors |
|
- Smoking
- High fat diet, excess body weight
- Family history of early MI
- Diabetes
- Second generation oral contraceptives
- Hostile, aggressive personality (Type A)
- Hypertension
- Hypercholesterolemia
- Males and postmenopausal females
- Cocaine or amphetamine abuse
|

|
|
Signs and Symptoms |
|
- Pain, heaviness, tightness, burning—in chest
(substernal), back, left arm, jaw, neck
- Dyspnea
- Dizziness, weakness
- Nausea, vomiting
- Anxiety
- Arrhythmia
- Hypotension,
hypertension
|

|
|
Differential
Diagnosis |
|
- Pulmonary embolism
- Unstable angina
- Esophagitis, or esophageal spasm
- Myocarditis
- Cholecystitis
- Pericarditis
- Aortic dissection
- Hiatal hernia
- Chest wall pains
- Pneumothorax
- Gastroenteritis
|

|
|
Diagnosis |
|
|
Physical Examination |
|
- "Crushing" chest pain, S4 gallop, ectopic impulse, systolic
murmurs
- Crackles—indicate elevated left ventricle
(LV) filling pressure
- Hypotension, elevated jugular venous pulse, clear lung
auscultation—indicate right ventricular
infarction
- S3 gallop—indicates systolic
dysfunction
|

|
|
Laboratory Tests |
|
- Serum cardiac enzymes increase as myocardial necrosis
evolves
- MB fraction of creatine kinase (CK-MB)—rises
within 6 hours, peaks within 24 hours, and declines within 72 hours of MI; gold
standard for diagnosis
- Lactate dehydrogenase (LDH)—rises after 24
hours, peaks three to six days and returns to normal in a week to 10 days;
increases diagnostic specificity
- Troponin T (cTnT) and cardiac-specific troponin I
(cTnI)—better sensitivity and specificity than CK-MB.
Serum levels increase 3 to 12 hours after MI, peak at 24 to 48 hours, and return
to baseline in 5 to 14 days.
|

|
|
Pathology/Pathophysiology |
|
- Atherosclerotic plaque leads to
platelet–fibrin thrombosis, resulting in coronary
artery occlusion
- Myocardium becomes ischemic, resulting in transmural spread of
necrosis
- Depth of plaque fissure, extent of atherosclerotic stenosis,
thrombogenic plaque constituents—determine magnitude of
thrombosis
|

|
|
Imaging |
|
- Chest X ray to differentiate pneumothorax
- CT/MRI or aortography to differentiate aortic dissection
- Noninvasive radionuclide imaging—shows
perfusion; e.g., technetium 99m sestamibi; for nondiagnostic ECGs, persistent
chest pain
|

|
|
Other Diagnostic
Procedures |
|
- Electrocardiogram (ECG)—diagnoses ventricular
dysrhythmias and monitors sinus tachycardia (ST)-segment changes
- History of symptoms; physical examination
- Test cardiac enzyme levels
- ST elevation—at least 1 mm in two contiguous
precordial leads or in inferior limb leads; appears early in MI
- Hyperacute T waves invert as ST segments return to normal
- Q waves often appear with ST elevation
- Left bundle branch block (LBBB)—Q waves in
V5 and V6 with 7 mm ST elevation
- Echocardiagram
- Two-dimensional—determines ventricular
function, wall and valvular abnormalities
- Doppler—diagnoses mitral regurgitation or
ventricular septal rupture
- Angiography—diagnoses coronary occlusion and
wall abnormalities for chest pain or nondiagnostic
ECG
|

|
|
Treatment Options |
|
|
Treatment Strategy |
|
- Immediate management of the patient aims to identify need for
reperfusion, relieve pain, provide oxygen, and prevent or treat complications of
MI.
- Rapid reperfusion can reduce infarct size, preserve ventricular
function, stop transmural spread of necrosis, increase electrical stability, and
reduce morbidity and mortality. There are three main methods of reperfusion:
thrombolytic therapy, percutaneous transluminal coronary angioplasty (PTCA) and
other mechanical reperfusion, and surgery.
- Treatment for all patients includes analgesics, nitroglycerin,
anticoagulants, antiplatelet therapy, beta-andrenergic antagonists, and oxygen
supplementation.
|

|
|
Drug Therapies |
|
Thrombolytic therapy. Ninety percent of patients with acute MI have complete
occlusion of the infarct-related artery.
- Perform within 60 to 90 minutes, little benefit after 12
hours
- Restores artery patency
Thrombolytic drugs include:
- Streptokinase—70 minutes to lysis; half-life
20 minutes; coronary patency: 55% at 90 minutes, 85% at 24 hours; antigenic; 1.5
million units intravenously in 30 to 60 minutes, slower if blood pressure
falls
- Tissue plasminogen activator (Alteplase,
rt-PA)—45 minutes to lysis; half-life 6 minutes;
coronary patency: 75% at 90 minutes, 85% at 24 hours; nonantigenic; 100 mg IV in
90 minutes; 15 mg bolus, then 0.75 mg/kg over 30 minutes, then 0.50 mg/kg over
60 minutes
- Anisoylated plasminogens streptokinase activator complex
(Anistreplase APSAC)—more expensive but longer
fibrinolytic activity than streptokinase; 30 mg IV in 5 minutes
- Reteplase (r-PA) is similar to alteplase, 10 units as a 2-minute
bolus, repeated after 30 minutes
- Aspirin—antiplatelet affect; 169 to 320 mg
then 85 mg for maintenance, consider contraindications
- Heparin—improves coronary patency,
controversial; best results with t-PA; 1,000 units/hour for 8 to 72
hours
- Contraindications for thrombolytic
therapy—severe bleeding, hypertension, liver or renal
disease, pregnancy, recent surgery,
stroke
|

|
|
Surgical Procedures |
|
PTCA—mechanical reperfusion
- Percutaneous transluminal coronary angioplasty
(PTCA)—Superior treatment; can reestablish arterial
blood flow in 90% of patients without some of the risks associated with
fibrinolytic agents. Few facilities can perform expeditiously.
- Intra-aortic balloon
counterpulsation—maintains perfusion; for hypotension,
ventricular rupture, mitral regurgitation; PTCA adjunct, CABG adjunct;
temporizing method prior to PTCA or CABG, or to allow heart to
recover
- Intracoronary stenting—stabilizes dissection
during PTCA
Coronary-artery bypass surgery (CABG)—for free wall
and acute septal rupture, mitral regurgitation, refractory cardiogenic shock. To
be utilized when the disease is too extensive for mechanical
repurfusion. |

|
|
General Measures |
|
- Analgesia—morphine sulfate 4 to 8 mg doses;
intravenous morphine 2 to 4 mg, can be repeated every 5 to 10 minutes
- Nitroglycerin—for recurrent ischemia,
congestive heart failure (CHF), hypertension: 0.4 mg sublingual, can be given
every five minutes in the absence of hypotension. Good response should be
followed by IV nitroglycerin at 10 mcg/minute.
- Antiplatelet therapy with aspirin—325 mg
chewed to enhance absorption
- Anticoagulants—for thromboembolic
complications. Heparin IV bolus of 80 units/kg followed by infusion of 18
units/kg/hour
- Oxygen—2 to 4 L per minute by nasal
cannula
- Angiotensin-converting enzyme (ACE)
inhibitors—reduce ventricular dilation and remodeling;
monitor renal function and hypotension. Captopril 6.25 mg orally, titrate to 25
to 50 mg orally tid over 24 to 48 hours.
- Beta-blockers—reduce cardiac rupture,
reinfarction, ventricular fibrillation. Metoprolol 5 mg, repeated every five
minutes to a total of 15 mg, then switch to oral metoprolol or
atenolol
|

|
|
Complementary and Alternative
Therapies |
|
Alternative therapies are most appropriate to prevent the first MI, minimize
damage from an MI, and reduce the risk of a future MI, once the patient has been
properly diagnosed and stabilized. There are no substitutes for immediate and
appropriate medical care with a presentation of chest pain and/or suspected MI.
See related subjects under angina, hypertension, and atherosclerosis.
|

|
|
Nutrition |
|
- L-carnitine (9 g/day IV for five days, then 6 g/day orally for 12
months) was studied within 24 hours of onset of chest pain and was found to
decrease left ventricular dilation.
- Diet: In another study, a diet high in antioxidants (vitamin C,
vitamin E, and beta-carotene), soluble dietary fiber, and one that replaces fat
with oils showed reduced plasma lipid peroxide and lactate dehydrogenase cardiac
enzyme levels. This may reduce myocardial necrosis and reperfusion
injury.
- Bromelain (400 to 800 mg/day) has been used for thrombolysis and may
help dissolve plaque.
|

|
|
Herbs |
|
Herbs should not be used in lieu of immediate medical attention. Herbs can be
used as general heart tonics and specifically applied to treating conditions
associated with MI, such as atherosclerosis, congestive heart failure,
hypercholesterolemia, hypertension, and
hypertriglyceridemia. |

|
|
Homeopathy |
|
Homeopathy should not be used in lieu of immediate medical attention. An
experienced homeopath should assess individual constitutional types and severity
of disease to select the correct remedy and potency of heart tonics.
|

|
|
Physical Medicine |
|
Beneficial for rehabilitation. |

|
|
Acupuncture |
|
Useful for pain and rehabilitation. |

|
|
Massage |
|
Beneficial for rehabilitation. |

|
|
Patient Monitoring |
|
Immediate:
- Electrocardiogram—2- to 3-lead
bedside
- Cardiac rate and rhythm
- Look for
complications
|

|
|
Other
Considerations |
|
|
Prevention |
|
Regular exercise, stress reduction, weight management, and avoidance or
management of risk factors |

|
|
Complications/Sequelae |
|
Electrical:
- Sinus bradycardia
- Ventricular or sinus tachycardia
- Atrial fibrillation
Mechanical:
- Rupture of free wall, interventricular septum, or papillary muscle
- Mitral regurgitation
- Hypertension
- LV failure/CHF
- Acute pericarditis
- Dressler's syndrome
- Cardiac arrest/sudden death
- Anxiety, depression
|

|
|
Prognosis |
|
Killip subgroups:
- Class I—no evidence of pulmonary congestion
or shock (mortality <5%)
- Class II—mild pulmonary congestion, isolated
S3 gallop (mortality 10%)
- Class III—pulmonary edema, LV dysfunction,
mitral regurgitation, S3 gallop, severe CHF (mortality 30%)
- Class IV—systemic hypoperfusion,
hypotension, cardiogenic shock (80%
mortality)
|

|
|
References |
|
Iliceto S, Scrutinio D, Bruzzi P, et al. Effects of L-carnitine
administration on left ventricular remodeling after acute anterior myocardial
infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico
(CEDIM) Trial. J Am Coll Cardiol. August 1995;26:380.
Kruzel T. The Homeopathic Emergency Guide. Berkeley, Calif: North
Atlantic Books; 1992:58-60.
Murray MT. The Healing Power of Herbs: The Enlightened Person's Guide to
the Wonders of Medicinal Plants. 2nd ed. Rocklin, Calif: Prima
Publishing; 1998:184.
Rakel RE, ed. Conn's Current Therapy. 50th ed. Philadelphia, Pa: WB
Saunders Co; 1998.
Singh RB, Niaz MA, Agarwal P, Begom R, Rastogi SS. Effect of antioxidant-rich
foods on plasma ascorbic acid, cardiac enzyme, and lipid peroxide levels in
patients hospitalized with acute myocardial infarction. J Am Diet Assoc.
July 1995;95:775-780.
Singh RB, Singh NK, Niaz MA, Sharma JP. Effect of treatment with magnesium
and potassium on mortality and reinfarction rate of patients with suspected
acute myocardial infarction. Int J Clin Pharmacol Thera. 1996;34:219-225.
Washington Manual of Medical Therapeautics. 29th ed. Philadelphia, Pa:
Lippincott-Raven Publishers;
1998. |

|
Copyright © 2000 Integrative Medicine
Communications This publication contains
information relating to general principles
of medical care that should not in any event be construed as specific
instructions for individual patients. The publisher does not accept any
responsibility for the accuracy of the information or the consequences arising
from the application, use, or misuse of any of the information contained herein,
including any injury and/or damage to any person or property as a matter of
product liability, negligence, or otherwise. No warranty, expressed or implied,
is made in regard to the contents of this material. No claims or endorsements
are made for any drugs or compounds currently marketed or in investigative use.
The reader is advised to check product information (including package inserts)
for changes and new information regarding dosage, precautions, warnings,
interactions, and contraindications before administering any drug, herb, or
supplement discussed herein. | |